Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome

Table 3 Changes in baseline to endpoint measures for insulin resistance in two groups

Variables		Mean ± SD Placebo(n = 28)	Mean ± SD Ellagic acid (n = 29)	P1
FBS (mg/dL)	Baseline	107.61 ± 20.13	111.17 ± 18.04	0.3
	End	106.17 ± 21.09	94.29 ± 17.43	0.043
	P2	0.622	0.035
	Mean Changes	-1.44 ± 0.96	-16.88 ± 0.61	0.04
Insulin (µU/ml)	Baseline	14.98 ± 3.07	15.41 ± 3.24	0.327
	End	14.04 ± 2.19	9.63 ± 1.31	0.03
	P2	0.541	0.027
	Mean Changes	-0.94 ± 0.88	-5.78 ± 1.93	0.041
HOMA-IR	Baseline	3.98 ± 0.85	4.22 ± 1.14	0.272
	End	3.68 ± 0.41	2.24 ± 0.5	0.04
	P2	0.158	0.031
	Mean Changes	-0.3 ± 0.44	-1.98 ± 0.64	0.043

Data are expressed as means ± SD. FBS Fasting Blood Sugar, HOMA-IR Homeostatic Model Assessment for Insulin Resistance
P1: Comparison of the mean of insulin resistance between the two groups of Ellagic acid and placebo (Independent samples t-test)
P2: Comparison of mean of insulin resistance in each group at baseline and end of study (Paired samples t-test)

ISSN: 1757-2215